
CLAIMS

1. A compound of Formula (I):




(I)

or a salt or solvate thereof, wherein:

X is CR_4;

A is:



;

Q_2 is -C(O)CH=CH_2, -C(O)CH=CH$CH_2N(CH_3)_2$, -C(O)C≡CR_7, -C(O)C≡C(phenyl), -C(O)C≡C(C_{1-3} hydroxyalkyl), -C(O)C≡C$Si(CH_3)_3$, or -S(O)$_2$CH=~~CH_2~~CHR_{10};

R_1 is H, -CH_3, -CF_3, or phenyl substituted with zero or 1 R_{12};

R_2 is H, -CH_3, cyclopropyl, or phenyl substituted with zero or 1 R_{12}, provided that ~~zero or one of R_1 and R_2 is phenyl substituted with zero or 1 R_{12} and further provided that~~ at least one of R_1 and R_2 is -CH_3;

R_3 is F or Cl;

R_4 is H or F;

R_7, at each occurrence, is independently H, C_{1-4} alkyl, or cyclopropyl; and

R_{12} is F, Cl, -CN, -CF_3, or C_{1-3} alkoxy.

2. The compound according to claim 1 or a salt or solvate thereof, wherein:


R_1 is ~~CH_3~~-CH_3 and R_2 is ~~CH_3~~-CH_3.

3. The compound according to claim 1 or a salt or solvate thereof, wherein:

R_3 is F.

4. The compound according to claim 1 or a salt or solvate thereof, wherein:
R_7 at each occurrence is H or C_{1-2} alkyl.

5. The compound according to claim 1 having the structure:



6. The compound according to claim 1 or a salt or solvate thereof, wherein said compound is selected from: (*S*)-4-(3-acrylamidopiperidin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(89)~~; (*S*)-4-(3-acrylamidopyrrolidin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(100)~~; (*S*)-5-fluoro-2,3-dimethyl-4-(3-(*N*-methylbut-2-ynamido)piperidin-1-yl)-1*H*-indole-7-carboxamide ~~(125)~~; (*S*)-5-fluoro-2,3-dimethyl-4-(3-(pent-2-ynamido) piperidin-1-yl)-1*H*-indole-7-carboxamide ~~(126)~~; (*S*)-5-fluoro-2,3-dimethyl-4-(3-(*N*-methylpent-2-ynamido)piperidin-1-yl)-1*H*-indole-7-carboxamide ~~(127)~~; (*S*)-5-fluoro-4-(3-(hex-2-ynamido)piperidin-1-yl)-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(128)~~; (*S*)-4-(3-(*N*-ethylbut-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(130)~~; (*S*)-4-(3-(but-2-ynamido)pyrrolidin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(135)~~; (*S*)-4-(3-(3-cyclopropylpropiolamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(136)~~;
(*S*)-5-fluoro-2,3-dimethyl-4-(3-(vinylsulfonamido)piperidin-1-yl)-1*H*-indole-7-carboxamide ~~(146)~~;
(*S*)-4-(3-(N-cyclopropylbut-2-ynamido) piperidin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-

carboxamide ~~(200)~~; 4-(4-(but-2-ynoyl)piperazin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-
carboxamide ~~(201)~~; 4-(4-acryloylpiperazin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(202)~~;
4-(1-acryloyl-1,2,5,6-tetrahydropyridin-3-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(216)~~; (*RS*)-4-(1-acryloylpiperidin-3-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide ~~(217)~~; 4-(1-acryloylpiperidin-3-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-7-carboxamide,
single enantiomers ~~(218 and 219)~~; (*RS*)-4-(1-(but-2-ynoyl) piperidin-3-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-
7-carboxamide ~~(220)~~; and (*S*)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1*H*-indole-
7-carboxamide ~~(223)~~.

7. A pharmaceutical composition comprising a compound according to any one of claims 1-6 or a pharmaceutically-acceptable salt or solvate thereof; and a pharmaceutically acceptable carrier.

8. A compound according to any one of claims 1-6 or a pharmaceutically-acceptable salt or solvate thereof, for use in therapy.

9. A compound according to any one of claims 1-6 or a pharmaceutically-acceptable salt or solvate thereof, for use in therapy in treating autoimmune disease or chronic inflammatory disease.

10. The compound ~~for use~~ according to claim 9 wherein said autoimmune disease or chronic inflammatory disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis (MS), and Sjögren's syndrome.

11. Use of the compound according to any one of claims 1-6 or a pharmaceutically-acceptable salt or solvate thereof, in the manufacture of a medicament for treating autoimmune disease or chronic inflammatory disease.

12. The use in claim 11, wherein said autoimmune disease or chronic inflammatory disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis (MS), and Sjögren's syndrome.